|
MXPA06002567A
(es)
|
2003-09-06 |
2006-09-04 |
Vertex Pharma |
Moduladores de transportadores con casete de union de atp.
|
|
EP1682127B1
(en)
*
|
2003-11-14 |
2009-07-29 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
|
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
MX341797B
(es)
|
2004-06-24 |
2016-09-02 |
Vertex Pharmaceuticals Incorporated * |
Moduladores de transportadores con casete de union con atp.
|
|
MX2008002019A
(es)
|
2005-08-11 |
2008-04-16 |
Vertex Pharma |
Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
|
|
ES2778846T3
(es)
|
2005-11-08 |
2020-08-12 |
Vertex Pharma |
Moduladores heterocíclicos de transportadores de casete de unión a ATP
|
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
AU2006336504C9
(en)
*
|
2005-12-28 |
2015-05-14 |
Vertex Pharmaceuticals Incorporated |
1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
|
|
LT1993360T
(lt)
|
2005-12-28 |
2017-06-12 |
Vertex Pharmaceuticals Incorporated |
N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
NZ596889A
(en)
|
2006-04-07 |
2013-06-28 |
Vertex Pharma |
Use of amide indole derivatives as modulators of ATP-binding cassette transporters
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
CN102863432B
(zh)
|
2007-05-09 |
2016-09-07 |
沃泰克斯药物股份有限公司 |
Cftr调节剂
|
|
HUE028426T2
(en)
*
|
2007-08-24 |
2016-12-28 |
Vertex Pharma |
Isothiazolopyridinones for (inter alia) treating cystic fibrosis
|
|
CN101821266B
(zh)
*
|
2007-09-14 |
2014-03-12 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜通道调节因子的调节剂
|
|
ES2556080T3
(es)
|
2007-11-16 |
2016-01-12 |
Vertex Pharmaceuticals Incorporated |
Moduladores de isoquinolina de transportadores de casete de unión a ATP
|
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
WO2009076142A2
(en)
|
2007-12-07 |
2009-06-18 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
|
|
KR20150063170A
(ko)
|
2007-12-07 |
2015-06-08 |
버텍스 파마슈티칼스 인코포레이티드 |
3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
|
|
EA201070699A1
(ru)
*
|
2007-12-07 |
2011-02-28 |
Вертекс Фармасьютикалз Инкорпорейтед |
Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
|
|
WO2009076593A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
CN106432213A
(zh)
|
2008-02-28 |
2017-02-22 |
沃泰克斯药物股份有限公司 |
作为cftr调节剂的杂芳基衍生物
|
|
EP2615085B1
(en)
*
|
2008-03-31 |
2015-08-26 |
Vertex Pharmaceuticals Incorporated |
Pyridyl derivatives as CFTR modulators
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
AU2009296271A1
(en)
*
|
2008-09-29 |
2010-04-01 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
NZ592685A
(en)
|
2008-10-23 |
2013-04-26 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US8367660B2
(en)
|
2008-12-30 |
2013-02-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
MX384179B
(es)
|
2009-03-20 |
2025-03-14 |
Vertex Pharma |
Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
BR112012026255A2
(pt)
|
2010-04-07 |
2017-03-14 |
Vertex Pharma |
composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
|
|
CN102933206A
(zh)
|
2010-04-07 |
2013-02-13 |
弗特克斯药品有限公司 |
3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
|
|
RU2745977C2
(ru)
|
2010-04-22 |
2021-04-05 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения циклоалкилкарбоксамидо-индольных соединений
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
KR101985044B1
(ko)
|
2011-11-08 |
2019-05-31 |
버텍스 파마슈티칼스 인코포레이티드 |
Atp-결합 카세트 수송체의 조절제
|
|
DK2806859T3
(da)
|
2012-01-25 |
2019-08-05 |
Vertex Pharma |
Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
|
|
JP2015511583A
(ja)
|
2012-02-27 |
2015-04-20 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
薬学的組成物およびその投与
|
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
MX2015015422A
(es)
|
2013-05-10 |
2016-06-21 |
Nimbus Apollo Inc |
Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
|
|
HK1221662A1
(zh)
|
2013-05-10 |
2017-06-09 |
Gilead Apollo, Llc |
Acc抑制剂和其用途
|
|
CN105358152A
(zh)
*
|
2013-05-10 |
2016-02-24 |
尼普斯阿波罗有限公司 |
Acc抑制剂和其用途
|
|
EA030958B1
(ru)
|
2013-05-10 |
2018-10-31 |
Джилид Аполло, Ллс |
Ингибиторы акк и их применение
|
|
DK3068392T5
(da)
|
2013-11-12 |
2021-09-20 |
Vertex Pharma |
Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
|
|
SG10201913575VA
(en)
|
2014-04-15 |
2020-02-27 |
Vertex Pharma |
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
|
|
ES2731802T3
(es)
*
|
2014-06-03 |
2019-11-19 |
Novartis Ag |
Derivados de naftiridinodiona como supresores de mutaciones sin sentido
|
|
EP3204358B1
(en)
|
2014-10-07 |
2018-09-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
|
MX2017005663A
(es)
|
2014-10-31 |
2018-03-01 |
Abbvie Sarl |
Tetrahidropiranos sustituidos y metodo de uso.
|
|
WO2016081556A1
(en)
|
2014-11-18 |
2016-05-26 |
Vertex Pharmaceuticals Incorporated |
Process of conducting high throughput testing high performance liquid chromatography
|
|
CN107922338A
(zh)
|
2015-06-02 |
2018-04-17 |
艾伯维公司 |
经取代的吡啶及使用方法
|
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
JP2018530557A
(ja)
|
2015-10-09 |
2018-10-18 |
アッヴィ・エス・ア・エール・エル |
置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用
|
|
KR20180083323A
(ko)
|
2015-10-09 |
2018-07-20 |
애브비 에스.에이.알.엘. |
N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법
|
|
EP3359540A1
(en)
|
2015-10-09 |
2018-08-15 |
AbbVie S.À.R.L. |
Novel compounds for treatment of cystic fibrosis
|
|
EP3448842A1
(en)
|
2016-04-26 |
2019-03-06 |
AbbVie S.À.R.L. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
EP3558982A1
(en)
|
2016-12-20 |
2019-10-30 |
AbbVie S.À.R.L. |
Deuterated cftr modulators and methods of use
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2019193062A1
(en)
|
2018-04-03 |
2019-10-10 |
Abbvie S.Á.R.L |
Substituted pyrrolidines and their use
|
|
EP3747882A1
(en)
|
2019-06-03 |
2020-12-09 |
AbbVie Overseas S.à r.l. |
Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
TW202115014A
(zh)
|
2019-07-12 |
2021-04-16 |
美商奧佛麥德公司 |
用於治療囊腫纖維化之化合物
|
|
CN114423769B
(zh)
|
2019-09-20 |
2024-04-26 |
Sabic环球技术有限责任公司 |
用于生产聚烯烃的催化剂组合物中的化合物
|
|
CA3157798A1
(en)
|
2019-11-12 |
2021-05-20 |
Zhongli Gao |
6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
|
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
US12324802B2
(en)
|
2020-11-18 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US20220213041A1
(en)
|
2021-01-06 |
2022-07-07 |
AbbVie Global Enterprises Ltd. |
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
|
|
WO2022150174A1
(en)
|
2021-01-06 |
2022-07-14 |
AbbVie Global Enterprises Ltd. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
PE20241330A1
(es)
|
2021-09-03 |
2024-06-26 |
Genzyme Corp |
Compuestos de indol y metodos de uso
|
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
|
WO2024054851A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocyclic compounds, compositions and methods of using thereof
|
|
KR20250091331A
(ko)
|
2022-09-07 |
2025-06-20 |
시오나 테라퓨틱스 인크. |
거대환식 화합물, 조성물, 및 이의 사용 방법
|
|
WO2024054845A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocycic compounds, compositions, and methods of using thereof
|
|
WO2025132358A1
(en)
|
2023-12-21 |
2025-06-26 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases
|